TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11811223

Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg (max 5mg/dose) plus MgO for 4 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Magnesium oxide (MgO) alone (125 mg three times a day for <20 kg or 250 mg three times a day for >20 kg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg (max 5mg/dose) plus MgO for 1 week
Number of subjects: 84

Group type: COMPARATOR
Intervention: Magnesium oxide (MgO) alone for 1 week
Number of subjects: 84
Study: 30745518

Group type: EXPERIMENTAL
Intervention: Fosravuconazole (100 mg, orally once a day for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29652237

Group type: EXPERIMENTAL
Intervention: Facet replacement surgery with the ACADIA facet replacement system
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Revision to titanium posterior spinal fusion and interbody fusion
Number of subjects: 2
Study: 26209166

Group type: EXPERIMENTAL
Intervention: Eldecalcitol at 0.75 μg/day and alendronate at 35 mg/week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alendronate at 35 mg/week
Number of subjects: 50
Study: 25385669

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal insert (PVI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular progesterone in oil (PIO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall patient preference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing pregnancy rates
Number of subjects: 0
Study: 22237871

Group type: EXPERIMENTAL
Intervention: 50% whey whole protein (50% WWP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 100% whey partially hydrolyzed protein (100% WPHP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Casein-based formula
Number of subjects: 13
Study: 20843369

Group type: EXPERIMENTAL
Intervention: Tailored Personalised Decision Support (PDS)
Number of subjects: 3240

Group type: EXPERIMENTAL
Intervention: Non-tailored Personalised Decision Support (PDS)
Number of subjects: 3240

Group type: COMPARATOR
Intervention: Usual practice (non-tailored paper-based approach)
Number of subjects: 3240

Group type: EXPERIMENTAL
Intervention: All groups (PDS and usual practice)
Number of subjects: 3240
Study: 16905564

Group type: COMPARATOR
Intervention: Conventional spacer
Number of subjects: 400

Group type: COMPARATOR
Intervention: Bottle spacer
Number of subjects: 400
Study: 16319891

Group type: COMPARATOR
Intervention: Salmeterol (long-acting bronchodilator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albuterol (short-acting beta2-agonist bronchodilator)
Number of subjects: 0
Study: 12487223

Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg orally daily for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9470169

Group type: EXPERIMENTAL
Intervention: M diet (modified milk fat with 16% of cholesterolemic saturated fatty acid replaced by mainly oleic and stearic acids)
Number of subjects: 18

Group type: COMPARATOR
Intervention: D diet (conventional Danish milk fat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: M diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: D diet
Number of subjects: 18
Study: 7628834

Group type: EXPERIMENTAL
Intervention: Diltiazem sustained-release (Mono-Tildiem LP 300 mg) with food intake
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diltiazem sustained-release (Mono-Tildiem LP 300 mg) without food intake
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diltiazem sustained-release (Mono-Tildiem LP 300 mg) at different times of administration
Number of subjects: 12
Study: 2689181

Group type: EXPERIMENTAL
Intervention: Nifedipine therapy
Number of subjects: 10
Study: 926022

Group type: EXPERIMENTAL
Intervention: Target stimuli (finger stimuli)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random four-finger experiments at a slower rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisensory paradigm with finger shocks and acoustic clicks
Number of subjects: 0
Study: 29631457

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 11

Group type: COMPARATOR
Intervention: Without Kinesio taping
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 28559255

Group type: EXPERIMENTAL
Intervention: MHAB5553A (120 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MHAB5553A (1,200 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MHAB5553A (3,600 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MHAB5553A (8,400 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MHAB5553A (10,800 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MHAB5553A
Number of subjects: 26
Study: 25062086

Group type: EXPERIMENTAL
Intervention: Myorelaxation Therapy (nocturnally applied non-occluding sublingual relaxation splint combined with daily stretching exercises)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control period (no interventions for 4 weeks)
Number of subjects: 78
Study: 23948337

Group type: EXPERIMENTAL
Intervention: Community-supported agriculture (CSA) intervention with 5 educational sessions and a box of fresh produce for 16 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no educational sessions or produce delivery)
Number of subjects: 50
Study: 21774822

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg daily; n = 28)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 60
Study: 19294756

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with adequate generation of the allocation sequence
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with adequate allocation concealment
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials that were double-blind
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with adequate sample size calculation
Number of subjects: 105

Group type: COMPARATOR
Intervention: Historical cohorts for comparison
Number of subjects: 105
Study: 16407883

Group type: COMPARATOR
Intervention: Constant TMP at around 300 mmHg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Profiled TMP (slowly increased from low to maximal value)
Number of subjects: 12
Study: 12568942

Group type: EXPERIMENTAL
Intervention: Effort coping
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Distress coping
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Effort-distress coping
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 10563276

Group type: EXPERIMENTAL
Intervention: Experimental group (0.3 cc metaproterenol in 2.5 cc of saline at times 0, 20", 40", 1', 2', 3', 4', 5', 6', and 7')
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (metaproterenol at times 0, 1 hr, and hours 3, 5, and 7; placebo at 20", 40", 2', 4', and 6')
Number of subjects: 71
Study: 8939269

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a solution of purified and biologically standardized extract of Parietaria judaica, following a preseasonal rush schedule.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (symptomatic drugs only)
Number of subjects: 40
Study: 1767322

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (15 ml of the drug in 200 ml of a 0.85% NaCl solution: 10 ml in the morning and 5 ml in the evening)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (same amount of solution as cerebrolysin)
Number of subjects: 60
Study: 6979980

Group type: EXPERIMENTAL
Intervention: Long interview (4 to 11 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Short interview (2 minutes)
Number of subjects: 60
Study: 30848023

Group type: EXPERIMENTAL
Intervention: McGRATH MAC videolaryngoscope
Number of subjects: 90

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 90
Study: 28323158

Group type: EXPERIMENTAL
Intervention: End-tidal sevoflurane concentration group (E)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Routine care group (R)
Number of subjects: 2500
Study: 25488963

Group type: EXPERIMENTAL
Intervention: Linifanib 17.5 mg once daily
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 1035
Study: 23274057

Group type: EXPERIMENTAL
Intervention: Non-medical prescription stimulants (NMPS)
Number of subjects: 4090

Group type: EXPERIMENTAL
Intervention: Non-medical prescription stimulants (NMPS) with alcohol
Number of subjects: 4090

Group type: COMPARATOR
Intervention: Past year drinkers who did not use prescription stimulants
Number of subjects: 4090

Group type: COMPARATOR
Intervention: Concurrent NMPS and alcohol users (use over the past year but not at the same time)
Number of subjects: 4090
Study: 21469915

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) for up to 15 months
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 17964655

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 607

Group type: COMPARATOR
Intervention: Medications
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Surgery (nonsmokers)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Surgery (smokers)
Number of subjects: 607
Study: 17067837

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (healthy age-matched women)
Number of subjects: 23
Study: 13680313

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Parathormone (PTH)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Calcitriol, fluoride, calcium, clodronate, etidronate, hormone replacement therapy, pamidronate, strontium, tiludronate, vitamin D
Number of subjects: 45
Study: 10832513

Group type: EXPERIMENTAL
Intervention: Current and previous users of MDMA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous users of MDMA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-users of MDMA)
Number of subjects: 0
Study: 9621491

Group type: EXPERIMENTAL
Intervention: Vinorelbine as a single agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with mitomycin C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with 5-fluorouracil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with ifosfamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with taxol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with taxotere
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with mitoxantrone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with epirubicin
Number of subjects: 0
Study: 8160227

Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit (n = 73)
Number of subjects: 146

Group type: COMPARATOR
Intervention: General wards (n = 68)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit
Number of subjects: 146

Group type: COMPARATOR
Intervention: General wards
Number of subjects: 146
Study: 3341527

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery
Number of subjects: 189
Study: 31378923

Group type: EXPERIMENTAL
Intervention: Cancellous allograft and d‐PTFE membrane at 2 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cancellous allograft and d‐PTFE membrane at 4 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cancellous allograft and d‐PTFE membrane at 6 months
Number of subjects: 49
Study: 29450731

Group type: EXPERIMENTAL
Intervention: mini-PCNL using 16.5 Fr percutaneous sheath
Number of subjects: 108

Group type: COMPARATOR
Intervention: ESWL using Dornier Compact Sigma
Number of subjects: 108
Study: 28394781

Group type: EXPERIMENTAL
Intervention: Active tPCS with bimastoid montage
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active tPCS with ear-clip montage
Number of subjects: 20
Study: 25779885

Group type: EXPERIMENTAL
Intervention: Prophylactic cefazolin (237 patients, 60.0%)
Number of subjects: 395

Group type: COMPARATOR
Intervention: No prophylactic antibiotics (158 patients, 40.0%)
Number of subjects: 395
Study: 23821974

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10/5/5 mg (immediately postoperatively and on day 1 and 2)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dexamethasone 20/10/10 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 62
Study: 20496107

Group type: EXPERIMENTAL
Intervention: Fresh semen from HIV-1 patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sperm migration after selection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: After freezing/thawing in HIV-1 patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: After freezing/thawing in control patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fresh sperm in HIV-1 patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Frozen/thawed sperm in HIV-1 patients
Number of subjects: 40
Study: 19099594

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine (ASAQ)
Number of subjects: 246
Study: 16283318

Group type: EXPERIMENTAL
Intervention: Amitriptyline (20 mg daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (healthy female controls)
Number of subjects: 30
Study: 12169073

Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg/d for 24 weeks)
Number of subjects: 369
Study: 9800058

Group type: EXPERIMENTAL
Intervention: Computerized corneal topography (CCT)
Number of subjects: 50
Study: 7614529

Group type: EXPERIMENTAL
Intervention: OPTI‐SOAK Conditioning Solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boston Advance Conditioning Solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boston Conditioning Solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barnes‐Hind Wetting and Soaking Solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duracare Conditioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total Cleaning, Wetting & Soaking Solution
Number of subjects: 0
Study: 2171596

Group type: EXPERIMENTAL
Intervention: Surgery + bestatin
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1030
Study: 102114

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) 80 mg daily for 3 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Amitriptyline 100 mg daily for 3 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TRH treatment
Number of subjects: 6
Study: 7035955

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30869969

Group type: EXPERIMENTAL
Intervention: Panic-focused psychodynamic psychotherapy (PFPP)
Number of subjects: 44
Study: 29874805

Group type: EXPERIMENTAL
Intervention: Cod‐PC (6 g/day of proteins from cod residuals as presscake meal)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cod‐PCW (6 g/day of proteins from cod residuals as presscake and stickwater meal)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo tablets (control)
Number of subjects: 42
Study: 27021752

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) intervention
Number of subjects: 0
Study: 24390777

Group type: EXPERIMENTAL
Intervention: Daily school physical education (PE) for 40 minutes
Number of subjects: 2621

Group type: COMPARATOR
Intervention: Control group with 60 minutes of PE per week
Number of subjects: 2621
Study: 22071290

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (energy and protein enriched diet, oral nutritional support, calcium‐vitamin D supplement, telephone counselling by a dietician)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 210
Study: 19602584

Group type: EXPERIMENTAL
Intervention: AICA-riboside infusion (2 mg x min(‐1) x dl(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: AICA-riboside infusion combined with caffeine (90 microg x min(‐1) x dl(‐1); n = 6)
Number of subjects: 24

Group type: COMPARATOR
Intervention: AICA-riboside infusion combined with l-NMMA (0.4 mg x min(‐1) x dl(‐1); n = 6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AICA-riboside infusion
Number of subjects: 24
Study: 17827465

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus thoracic radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thoracic radiation alone
Number of subjects: 0
Study: 15924805

Group type: COMPARATOR
Intervention: 10 mg simvastatin
Number of subjects: 221

Group type: COMPARATOR
Intervention: 200 mg fenofibrate
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin + 200 mg fenofibrate
Number of subjects: 221
Study: 11895286

Group type: EXPERIMENTAL
Intervention: PRP/BPBM
Number of subjects: 21

Group type: COMPARATOR
Intervention: PRP/BPBM/GTR
Number of subjects: 21
Study: 10464844

Group type: EXPERIMENTAL
Intervention: Heated humidification (HC 100, Fischer & Paykel, Inc.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oily nose drops (Colda-Stop, Desitin, Inc.)
Number of subjects: 24
Study: 8703644

Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.25 mg h‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.50 mg h‐1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 45
Study: 2142054

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tolbutamide
Number of subjects: 20
Study: 724184

Group type: EXPERIMENTAL
Intervention: Training on a professional patient
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training on a plastic model
Number of subjects: 0
Study: 31691462

Group type: EXPERIMENTAL
Intervention: Open-label caplacizumab
Number of subjects: 31

Group type: COMPARATOR
Intervention: Double-blind treatment (caplacizumab)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (during double-blind treatment)
Number of subjects: 31
Study: 31385562

Group type: EXPERIMENTAL
Intervention: ZuraGard (ZG)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Chloraprep (CP)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Negative control (ZV)
Number of subjects: 2
Study: 28181131

Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control
Number of subjects: 162
Study: 26718395

Group type: EXPERIMENTAL
Intervention: Telephone-based continuing care (TEL)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Standard continuing care (STD)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Relapse prevention (RP)
Number of subjects: 359
Study: 24046466

Group type: EXPERIMENTAL
Intervention: Closed suction catheter with a valve (Ballard Trach Care 72)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Closed suction catheter without a valve (Portex Steri‐Cath DL)
Number of subjects: 10
Study: 22313580

Group type: EXPERIMENTAL
Intervention: 80 mg depo‐methylprednisolone + 0.5% lidocaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.5% lidocaine
Number of subjects: 88
Study: 20018155

Group type: EXPERIMENTAL
Intervention: Retroactive remote intercessory prayer for patients already dead or dismissed
Number of subjects: 36
Study: 17464703

Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.8-1.8 mg kg(‐1) day(‐1))
Number of subjects: 330

Group type: COMPARATOR
Intervention: Methylphenidate (0.2-0.6 mg kg(‐1) day(‐1))
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 330

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 330
Study: 15024302

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (LGBP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Open gastric bypass (OGBP)
Number of subjects: 104
Study: 12113380

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (PRP) for 8 weeks including supervised incremental exercise
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (PRP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Patients with cor pulmonale
Number of subjects: 47
Study: 10204833

Group type: EXPERIMENTAL
Intervention: 1000 mg ascorbic acid
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: COMPARATOR
Intervention: 200 mg ascorbic acid
Number of subjects: 75
Study: 7596492

Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 178

Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 178
Study: 2354800

Group type: EXPERIMENTAL
Intervention: Informational mini-lecture series
Number of subjects: 66

Group type: COMPARATOR
Intervention: Peer networks
Number of subjects: 66
Study: 369472

Group type: EXPERIMENTAL
Intervention: Lithium carbonate plus haloperidol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo plus haloperidol
Number of subjects: 36
Study: 30009627

Group type: EXPERIMENTAL
Intervention: Early motion protocol (active and passive wrist motion by 14 days after surgery)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Late motion protocol (delayed motion initiated at 5 weeks)
Number of subjects: 33
Study: 31821294

Group type: EXPERIMENTAL
Intervention: Bone patellar tendon bone allograft (BPTB)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Hamstring tendon autograft (GST)
Number of subjects: 43
Study: 27129607

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Home-Based Exercise (HBE)
Number of subjects: 152
Study: 26913620

Group type: EXPERIMENTAL
Intervention: Parent social‐cognitive intervention program (P‐SCIP)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Best-practice psychosocial care (BPC)
Number of subjects: 218
Study: 25399658

Group type: EXPERIMENTAL
Intervention: Thienopyridine treatment
Number of subjects: 9961